From Real Exams Exam Paper

A Level H2 Economics Practice Paper 2

Free A Level H2 Econs Practice Paper 2, Gemma31B Exam version, with questions, answers, and A Level-style practice for Singapore students.

These static practice materials are generated from the site's syllabus and paper-generation workflow, with source and model context shown so students and parents can evaluate the material before use.

A Level H2 Economics From Real Exams Generated by Gemma 4 31B Updated 2026-08-17

Questions

Free quiz and exam paper access

Enter your details to view this paper

Your access is remembered on this device.

Answers

Marking Scheme: TuitionGoWhere Exam Practice (AI)

Subject: Economics H2 | Paper: Paper 1 (Microeconomics Case Study)


Section A: Data Interpretation and Analysis

1. (a) Relationship between HPC chips and AI health diagnostics [3]

  • Identification: HPC chips are a key input (factor of production) for AI health diagnostics. [1]
  • Explanation: There is a complementary relationship. An increase in the price of HPC chips increases the marginal cost of providing diagnostic services. [2]

2. (b) Diagram and Effect of Price Increase [4]

  • Diagram: Supply and Demand graph. Supply curve shifts left/upwards (S0S_0 to S1S_1). [2]
  • Analysis: The shift in supply leads to a higher equilibrium price (P0P_0 to P1P_1) and a lower equilibrium quantity (Q0Q_0 to Q1Q_1). [2]

3. (c) Passing on costs (Price Inelasticity) [3]

  • Concept: Price Elasticity of Demand (PED) is low/inelastic. [1]
  • Reasoning: Consumers perceive the services as essential/life-saving (lack of close substitutes). [1]
  • Conclusion: Therefore, a price increase results in a proportionately smaller decrease in quantity demanded, allowing firms to maintain revenue while passing on costs. [1]

Section B: Market Structures and Competition

4. (a) Market Structure [4]

  • Identification: Oligopoly. [1]
  • Evidence: Extract 1 states "Two major firms, HealthAI and MediScan, dominate the landscape." [2]
  • Characteristic: High concentration ratio and high barriers to entry (patents mentioned). [1]

5. (b) Nature of Competition [6]

  • Non-Price Competition: Firms are likely to compete via branding, quality of AI accuracy, and specialized services (e.g., the cancer detection patents). [3]
  • Interdependence: Because there are only two dominant firms, HealthAI’s pricing or service decisions will directly influence MediScan’s strategy (game theory/strategic interaction). [3]

6. (c) Acquisition of BioCheck: Benefit vs Disadvantage [15]

  • Disadvantages (Market Power):
    • Increased market concentration \rightarrow higher monopoly power.
    • Potential for higher prices due to reduced competition.
    • Reduced incentive to innovate if HealthAI becomes too dominant.
  • Benefits (Efficiencies):
    • Dynamic Efficiency: HealthAI may have more capital to invest in BioCheck's patents, accelerating the development of cancer detection.
    • Economies of Scale: Integration may lower average costs through shared infrastructure.
  • Evaluation:
    • Depends on whether the efficiency gains (better diagnostics) outweigh the allocative inefficiency (higher prices).
    • Role of government regulation (e.g., Competition and Consumer Commission of Singapore) in preventing abuse of dominance.